Mild to Moderate COVID-19
9
0
0
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 67/100
22.2%
2 terminated out of 9 trials
66.7%
-19.8% vs benchmark
44%
4 trials in Phase 3/4
0%
0 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (9)
A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients
Phase III Clinical Study Evaluating the Efficacy and Safety of WPV01 in Patients With Mild/Moderate COVID-19
JT001 (VV116) for the Early Treatment of COVID-19
JT001 (VV116) for the Treatment of COVID-19
Study of RAY1216 Tablets Compared With Placebo in Patients With Mild to Moderate COVID-19
Evaluate the Efficacy and Safety of FB2001 for Inhalation in Patients With Mild to Moderate COVID-19
Efficacy and Safety of DWJ1248 in Patients With Mild to Moderate COVID-19 Compared to the Placebo
Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)
Fluvoxamine for Adults With Mild to Moderate COVID-19